Institution
Marche Polytechnic University
Education•Ancona, Italy•
About: Marche Polytechnic University is a education organization based out in Ancona, Italy. It is known for research contribution in the topics: Population & Prostate cancer. The organization has 5905 authors who have published 15769 publications receiving 382286 citations. The organization is also known as: Universitá Politecnica delle Marche & Universita Politecnica delle Marche.
Topics: Population, Prostate cancer, Cancer, Mediterranean sea, Electromagnetic reverberation chamber
Papers published on a yearly basis
Papers
More filters
Hannover Medical School1, University of Bonn2, National Institute for Health Research3, Karolinska University Hospital4, University of North Dakota5, Mayo Clinic6, Oslo University Hospital7, University Hospital Heidelberg8, University of Helsinki9, University of Gothenburg10, Royal Free Hospital11, University Medical Center Groningen12, Katholieke Universiteit Leuven13, Charité14, Pierre-and-Marie-Curie University15, University of Hamburg16, Linköping University17, University College London18, University of Miami19, University of Alberta20, University of Oslo21, University of California, Davis22, University of Padua23, Medical University of Vienna24, California Pacific Medical Center25, Pomeranian Medical University26, Medical University of Warsaw27, Royal Adelaide Hospital28, University of Barcelona29, University of Zurich30, University of Thessaly31, University of Calgary32, University of Milan33, University of Tübingen34, Goethe University Frankfurt35, Saarland University36, Marche Polytechnic University37, University of Oxford38, John Radcliffe Hospital39, Arizona State University40, Toronto General Hospital41, University of Toronto42, Erasmus University Medical Center43
TL;DR: In an analysis of data from individual patients with PSC worldwide, significant variation in clinical course associated with age at diagnosis, sex, and ductal and IBD subtypes is found.
334 citations
TL;DR: In this article, the authors investigated the performance of green roofs in terms of their expected benefits for the building and the urban environment, due to their recognised energy and water management potential scores.
333 citations
TL;DR: In a methotrexate-naive population with early RA and poor prognostic factors, the combination of abatacept and methotRexate provided significantly better clinical and radiographic efficacy compared with methot Rexate alone and had a comparable, favourable safety profile.
Abstract: Objectives: To assess the efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis (RA) and poor prognostic factors. Methods: In this double-blind, phase IIIb study, patients with RA for 2 years or less were randomly assigned 1 : 1 to receive abatacept (similar to 10 mg/kg) plus methotrexate, or placebo plus methotrexate. Patients were methotrexate-naive and seropositive for rheumatoid factor (RF), anti-cyclic citrullinated protein (CCP) type 2 or both and had radiographic evidence of joint erosions. The co-primary endpoints were the proportion of patients achieving disease activity score in 28 joints (DAS28)-defined remission (C-reactive protein) and joint damage progression (Genant-modified Sharp total score; TS) at year 1. Safety was monitored throughout. Results: At baseline, patients had a mean DAS28 of 6.3, a mean TS of 7.1 and mean disease duration of 6.5 months; 96.5% and 89.0% of patients were RF or anti-CCP2 seropositive, respectively. At year 1, a significantly greater proportion of abatacept plus methotrexate-treated patients achieved remission (41.4% vs 23.3%; p<0.001) and there was significantly less radiographic progression (mean change in TS 0.63 vs 1.06; p = 0.040) versus methotrexate alone. Over 1 year, the frequency of adverse events (84.8% vs 83.4%), serious adverse events (7.8% vs 7.9%), serious infections (2.0% vs 2.0%), autoimmune disorders (2.3% vs 2.0%) and malignancies (0.4% vs 0%) was comparable for abatacept plus methotrexate versus methotrexate alone. Conclusions: In a methotrexate-naive population with early RA and poor prognostic factors, the combination of abatacept and methotrexate provided significantly better clinical and radiographic efficacy compared with methotrexate alone and had a comparable, favourable safety profile.
331 citations
TL;DR: In this article, the authors analyzed heat pumps with radiators or underfloor heating distribution systems coupled with thermal energy storage (TES) with a view to showing how a heat pump system behaves and how it influences the building occupants' thermal comfort under a DSM strategy designed to flatten the shape of the electricity load curve by switching off the heat pump during peak hours.
329 citations
TL;DR: GATs may play a role in the complex processes regulating cortical maturation and contribute to the dysregulation of neuronal excitability that accompanies at least two major human diseases: epilepsy and ischemia.
328 citations
Authors
Showing all 6013 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Jonathan I. Epstein | 138 | 1121 | 80975 |
| Antoni Ribas | 132 | 660 | 99227 |
| Francesco Fiori | 128 | 1032 | 76699 |
| Claudio Franceschi | 120 | 856 | 59868 |
| Robert E. Coleman | 103 | 724 | 49796 |
| Carmine Zoccali | 99 | 813 | 36774 |
| Massimo Falconi | 94 | 667 | 41966 |
| Mario Plebani | 91 | 1329 | 43055 |
| Roberto Danovaro | 84 | 415 | 23735 |
| Rodolfo Montironi | 83 | 958 | 30957 |
| Diego Centonze | 81 | 463 | 22857 |
| Saverio Cinti | 78 | 256 | 32760 |
| Michele Brignole | 76 | 399 | 26758 |
| Jürgen P. Rabe | 76 | 391 | 20174 |
| Jean-Jacques Body | 70 | 384 | 19608 |